everolimus
Selected indexed studies
- Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. (Expert Opin Pharmacother, 2018) [PMID:29757017]
- Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. (Expert Rev Neurother, 2019) [PMID:31335226]
- Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates. (Pediatr Res, 2025) [PMID:40287604]
_Worker-drafted node — pending editorial review._
Connections
everolimus is a side effect of
Sources
- Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. (2018) pubmed
- Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. (2019) pubmed
- Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates. (2025) pubmed
- Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. (2020) pubmed
- Everolimus therapy and side‑effects: A systematic review and meta‑analysis. (2021) pubmed
- Everolimus in pediatric transplantation. (2012) pubmed
- Durable polymer everolimus-eluting stents: history, current status and future prospects. (2020) pubmed
- Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). (2019) pubmed
- Effects of Everolimus in Modulating the Host Immune Responses against Mycobacterium tuberculosis Infection. (2023) pubmed
- Everolimus in de novo liver transplant recipients: a systematic review. (2015) pubmed